StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd. (ONC) stock

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302571% above fair value
$403.60−9.66 (-2.34%)

Close on Nov 18, 2026Market cap $45.89BP/E 72.2Yield –

BeOne Medicines revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

BeOne Medicines's revenue for the twelve months ending Jun 30, 2026 was $6.13B, up 34.3% year over year. For fiscal 2025 it was $5.34B, up 40.2% from the year before. Over ten years it grew 89.8% a year on average. The highest annual figure on record is $5.34B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$5.34B+40.2%
FY2024Dec 31, 2024$3.81B+55.0%
FY2023Dec 31, 2023$2.46B+73.7%
FY2022Dec 31, 2022$1.42B+20.4%
FY2021Dec 31, 2021$1.18B+280.8%
FY2020Dec 31, 2020$308.87M-27.9%
FY2019Dec 31, 2019$428.21M+116.0%
FY2018Dec 31, 2018$198.22M-16.8%
FY2017Dec 31, 2017$238.39M+22179.2%
FY2016Dec 31, 2016$1.07M-87.9%
FY2015Dec 31, 2015$8.82M-32.4%
FY2014Dec 31, 2014$13.04M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.71B+29.6%
Q1 FY2026Mar 31, 2026$1.51B+35.5%
Q4 FY2025Dec 31, 2025$1.50B+32.8%
Q3 FY2025Sep 30, 2025$1.41B+41.0%
Q2 FY2025Jun 30, 2025$1.32B+41.6%
Q1 FY2025Mar 31, 2025$1.12B+48.6%
Q4 FY2024Dec 31, 2024$1.13B+77.8%
Q3 FY2024Sep 30, 2024$1.00B+28.2%
Q2 FY2024Jun 30, 2024$929.17M+56.1%
Q1 FY2024Mar 31, 2024$751.65M+67.9%
Q4 FY2023Dec 31, 2023$634.41M+66.9%
Q3 FY2023Sep 30, 2023$781.31M+101.6%
Q2 FY2023Jun 30, 2023$595.26M+74.3%
Q1 FY2023Mar 31, 2023$447.80M+46.0%
Q4 FY2022Dec 31, 2022$380.10M+77.6%
Q3 FY2022Sep 30, 2022$387.63M+87.8%
Q2 FY2022Jun 30, 2022$341.57M+127.7%
Q1 FY2022Mar 31, 2022$306.63M-49.4%
Q4 FY2021Dec 31, 2021$213.98M+113.8%
Q3 FY2021Sep 30, 2021$206.44M+126.7%
Q2 FY2021Jun 30, 2021$149.99M+128.5%
Q1 FY2021Mar 31, 2021$605.87M+1063.8%
Q4 FY2020Dec 31, 2020$100.10M+75.9%
Q3 FY2020Sep 30, 2020$91.08M+81.6%
Q2 FY2020Jun 30, 2020$65.64M-73.0%
Q1 FY2020Mar 31, 2020$52.06M-33.1%
Q4 FY2019Dec 31, 2019$56.89M-3.0%
Q3 FY2019Sep 30, 2019$50.14M-7.5%
Q2 FY2019Jun 30, 2019$243.35M+360.8%
Q1 FY2019Mar 31, 2019$77.83M+139.2%
Q4 FY2018Dec 31, 2018$58.67M+222.8%
Q3 FY2018Sep 30, 2018$54.20M-75.4%
Q2 FY2018Jun 30, 2018$52.80M–
Q1 FY2018Mar 31, 2018$32.54M–
Q4 FY2017Dec 31, 2017$18.17M–
Q3 FY2017Sep 30, 2017$220.21M–
Q2 FY2017Jun 30, 2017$0–
Q1 FY2017Mar 31, 2017$0–
Q4 FY2016Dec 31, 2016$0–
Q3 FY2016Sep 30, 2016$0–

More BeOne Medicines figures

See a number that looks wrong?